New recommendations on the use of testosterone therapy in women have been published.
The recommendations are contained in a new position statement which has been endorsed by the International Menopause Society, the Endocrine Society, the European Menopause and Andropause Society, the International Society for Sexual Medicine, the International Society for the Study of Women's Sexual Health, the North American Menopause Society, the Federacion Latinoamericana de Sociedades de Climaterio y Menopausia, the Royal College of Obstetricians and Gynecologists, the International Society of Endocrinology, the Endocrine Society of Australia and the Royal Australian and New Zealand College of Obstetricians and Gynecologists.
Key recommendations include:
- The only evidence-based indication for the use of testosterone in women is for the treatment of post-menopausal women who have been diagnosed as having hypoactive sexual desire disorder/dysfunction (HSDD) after formal biopsychosocial assessment.
- Blood total testosterone level should not be used to diagnose HSDD.
- Treatment should only be with formulations that achieve blood concentrations of testosterone that approximate pre-menopausal physiological concentrations.
- Because no approved female product is presently approved, male formulations can be used in female doses; blood testosterone concentrations must be monitored.
- Compounded testosterone is not recommended.
- Caution is recommended for testosterone use in women with hormone-sensitive breast cancer.